PHILADELPHIA, Aug. 26, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors in RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).

RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).

On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."

On this news, RxSight shares fell $4.84, or 37%, to a clo

See Full Page